Search

Your search keyword '"Gandaglia G"' showing total 2,024 results

Search Constraints

Start Over You searched for: Author "Gandaglia G" Remove constraint Author: "Gandaglia G"
2,024 results on '"Gandaglia G"'

Search Results

3. The impact of centralized uropathology review in the management of bladder cancer patients at the time of transurethral resection of the bladder

4. Which is the optimal multimodal management of pN1 patients with PSA persistence after radical prostatectomy and extended nodal dissection? Results of a large, multi-institutional database

5. The impact of multiple lesions in prostate MRI – insights from the YAU prostate cancer group

6. PSA doubling time thresholds in predicting clinical recurrence after biochemical recurrence in surgically treated prostate cancer patients. The Impact of nodal status and adjuvant radiotherapy

7. Does the accuracy of PSA density change according to prostate volume? Assessing the diagnostic accuracy at the extreme values of prostate volume in a large single institution series

8. The quantification of GSP4 volume is superior to ISUP GG classification and %GSP4 for predicting adverse outcomes in radical prostatectomy patients

9. Defining intermediate-risk non-muscle invasive bladder cancer: A comparative study of EAU and IBCG criteria

11. The highest grade group does not drive the risk of advanced stage when systematic and multiparametric Magnetic Resonance Imaging (MRI)-targeted biopsies are discordant: Results from a large multi-institutional series

12. Assessing epigenetic features associated with lymph node metastases in prostate cancer

13. PSMA-PET vs. conventional imaging for preoperative staging high-risk PCa patients underwent surgery for cN0M0 disease

14. Optimizing detection and prediction of prostate cancer after positive MRI and negative biopsies

15. Age-dependent effect of early salvage radiotherapy for biochemical recurrence in prostate cancer patients treated with radical prostatectomy

16. The significant added value of concomitant systematic prostate biopsies in addition to targeted sampling in patients with previous negative biopsies. Implications for accurate staging predictions from a large multi-institutional series

17. PSMA radio-guided surgery to detect nodal metastases in prostate cancer patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection: Updated results of a planned interim analysis of a prospective phase 2 study

18. Urological follow-up of Lynch syndrome: UTUC incidence and mutational patterns in a dedicated outpatient clinic

20. The more you see the more you miss. PSMA PET/CT is still affected by a substantial risk of underestimation in prostate cancer patients undergoing radical prostatectomy

21. Cancer control rates in adequate versus inadequate treatment with adjuvant immunotherapy instillations with BCG

22. External validation of the available nomograms for the identification of candidates for a staging extended pelvic lymph node dissection at the time of radical prostatectomy in prostate cancer patients preoperatively staged with PSMA PET

23. Identifying the optimal definition of PSA response after metastasis directed therapy in men with oligo-recurrent prostate cancer detected at PSMA PET

24. Clinical characteristics of patients with renal cancer do impact more than ischemia time on post-operative renal function

25. Long-term oncological outcomes of surgically managed very high-risk prostate cancer patients according to the STAMPEDE trial definition: Implications for the selection of candidates for clinical trials

26. Impact of neoadjuvant chemo-immunotherapy on intra and post operative outcomes in patients with bladder cancer treated with radical cystectomy and pelvic lymph node dissection: Prospective surgical assessment from the NURE-Combo Trial

27. Oncologic outcomes of template vs. radio-guided salvage lymph node dissection for node-only recurrent prostate cancer: Results from a multi-institutional collaboration

28. Development of prostate cancer typical case presentations and their usage in OPTIMA’s guideline based decision support tool

29. Validation of the EAU risk groups for radical prostatectomy prostate cancer patients who experienced biochemical recurrence restaged with PSMA PET imaging and development of a novel tool

30. Do incidental prostate cancer patients managed with active surveillance exhibit different disease features and outcomes compared to their biopsy-diagnosed counterparts? Results of a multi-institutional study

31. A novel PRECISE implemented predictive model to assess the risk of long-term disease reclassification in men on active surveillance. Results from a large, single institution series

32. The role of artificial intelligence for the detection of clinically significant prostate cancer at multiparametric magnetic resonance imaging

33. Optimizing the number of systematic cores during MRI target biopsy. Preliminary results from the prospective, paired-cohort SCOT Trial

34. Effect of Metastasis Directed Therapy (MDT) in men with PSMA PET detected recurrent prostate cancer according to time from primary treatment. Do men with late recurrences really benefit from MDT? Results from a large, single institution series

35. The importance of high volume providers in the diagnostic pathways of prostate cancer. Results from large, singe Institution series

36. When does systematic biopsy information matter the most? Identifying independent predictors of disease downgrading at radical prostatectomy in high grade prostate cancer based on a large multi-institutional series

37. Towards a tailored use of PSA density to decide when to avoid prostate biopsy in men with PIRADS 3 lesions according to the location of the index lesion at mp-MRI. Results of a large, multi-institutional series

38. Oncological outcomes of pN1 prostate cancer patients treated with radical prostatectomy: Does molecular imaging have a prognostic impact? Results of a large, multi-institutional series

39. Can we rely on available models predicting pathological outcomes in prostate cancer patients staged with 68-Ga PSMA-PET/CT? External validation of the existing nomograms for extracapsular extension and seminal vesicle invasion at radical prostatectomy and development of a novel tool including intraprostatic SUVmax

40. How can we reduce the rates of false positive findings at mpMRI? The pivotal role of urologist expertise assessed in a large, single center series

41. Adjuvant or early salvage radiotherapy in node positive prostate cancer patients: Development of a novel risk score to identify the optimal candidate for early intensification approaches based on a large, multi-institutional series

43. Second line PSMA-targeted salvage treatment in patients with mi N1/M1a-b oligorecurrent PCa

44. Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on PSMA-PET: Results of a Multicenter, European Study

45. How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis

47. Orthotopic neobladder reconstruction following robot-assisted radical cystectomy: Systematic review of clinical outcomes and step-by-step description

48. How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis

50. When is central histological review of prostate biopsy really needed to reduce the risk of misclassification of prostate cancer? The importance of patient risk stratification

Catalog

Books, media, physical & digital resources